Department of Oncology, Shanxi Province Hospital of Traditional Chinese Medicine, Taiyuan, China.
Medicine (Baltimore). 2021 Dec 10;100(49):e27850. doi: 10.1097/MD.0000000000027850.
CRC, the incidence of the fourth highest among males and the third among females, is one of the malignant tumors that seriously threaten human health. The principle of treatment for advanced stage CRC is a multidisciplinary and comprehensive treatment based on chemotherapy, which always bring significant toxic side effects. CHM has advantages in the treatment of tumors with the effect on improving clinical symptoms and reducing side effects. GGQL formula is mainly used for treating abnormal defecates caused by damp-heat, so we will evaluate the clinical efficacy and safety of modified GGQL formula for patients with advanced CRC with the type of damp-heat in this study.
Multicenter RCT with two parallel groups in three hospitals planning to recruit 120 CRC patients with the type of damp-heat will be conducted. The control group will be treated by basic antitumor therapy and the treatment group will use modified GGQL formula plus basic antitumor therapy. The primary outcomes will be quality of life, TCM symptom score, PFS and OS, and the secondary outcomes will be performance status, size of tumor, tumor marker in the serum, tumor microenvironment and immune status. All analyses will be based on an intention-to-treat principle. This study was approved by the Human Research Ethics Committee of Shanxi Province Hospital of Traditional Chinese medicine (2021Y-06017). The results will be published in relevant journal.
The results of this RCT will contribute to Chinese herbal medicine for treating CRC patients with the type of damp heat accumulation.
ChiCTR2100050754 (September 4, 2021).
CRC 在男性中的发病率位居第四,在女性中位居第三,是严重威胁人类健康的恶性肿瘤之一。晚期 CRC 的治疗原则是以化疗为基础的多学科综合治疗,其往往会带来显著的毒副作用。中医药在改善临床症状、减轻毒副作用方面具有优势。固本灌肠液主要用于治疗湿热蕴结所致的大便异常,因此,我们将在这项研究中评估固本灌肠液加减方治疗湿热型晚期 CRC 患者的临床疗效和安全性。
本研究为三所医院开展的、以 120 例湿热型 CRC 患者为对象的、两组平行对照、多中心 RCT。对照组采用基础抗肿瘤治疗,观察组采用固本灌肠液加减方联合基础抗肿瘤治疗。主要结局指标为生活质量、中医证候评分、无进展生存期(PFS)和总生存期(OS),次要结局指标为体力状况、肿瘤大小、血清肿瘤标志物、肿瘤微环境和免疫状态。所有分析均基于意向性治疗原则。本研究已获得山西省中医院伦理委员会的批准(2021Y-06017)。研究结果将发表在相关期刊上。
这项 RCT 的结果将有助于中医药治疗湿热蕴结型 CRC 患者。
ChiCTR2100050754(2021 年 9 月 4 日)。